Gsk (GLAXF) Non Operating Income (2009 - 2026)

Gsk's Non Operating Income history runs 18 years deep, the most recent figure standing at $195.5 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 43.71% year-over-year to $195.5 million; the TTM figure through Mar 2026 stood at -$838.2 million (down 86.55% YoY), while the FY2025 annual figure was $701.4 million, changed 0.32% from the prior year.
• Non Operating Income was $195.5 million for Q1 2026 at Gsk, up from -$698.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $265.7 million in Q1 2022 to a low of -$919.6 million in Q4 2022.
• Historically, Non Operating Income has averaged -$144.4 million across 5 years, with a median of -$48.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income jumped 201.41% in 2022, then slumped 172.04% in 2025.
• A 5-year view of Non Operating Income shows it stood at -$919.6 million in 2022, then jumped by 65.72% to -$315.3 million in 2023, then rose by 18.57% to -$256.7 million in 2024, then plunged by 172.04% to -$698.3 million in 2025, then surged by 127.99% to $195.5 million in 2026.
• The last three Non Operating Income figures came in at $195.5 million (Q1 2026), -$698.3 million (Q4 2025), and -$45.9 million (Q3 2025), per Business Quant data.